Tirzepatide, a GLP-1 medication already on the market to treat diabetes, is now FDA approved to help those suffering from ...

Veterans with apnea-hypopnea index scores implying no sleep apnea or severe sleep apnea had higher all-cause mortality rates ...

Portable Oxygen Concentrator Market. According to a revised research study by Future Market Insights, the global portable ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Health, education, transport and law and order are still important, but Prime Minister Christopher Luxon is travelling the ...

Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...

Advanced Fertility Center of Chicago (AFCC), a premier provider of comprehensive and best-in-class fertility services, congratulates Dr. Michelle Catenacci on being named a 2025 Castle Connolly Top ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Introduction to Digital Health and WellnessThe digital health and wellness industry is experiencing significant growth as healthcare increasingly incorporates technology to improve the quality, ...

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its price target increased by equities researchers at Mizuho from ...

SG Americas Securities LLC decreased its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 69.3% ...

As more research is published about the health benefits associated with GLP-1s, like sleep apnea, heart disease, and ...